Aurinia Pharmaceuticals (AUPH) Capital Leases (2023 - 2026)
Aurinia Pharmaceuticals' (AUPH) quarterly Capital Leases came in at $48.2 million in Q1 2026, down 15.22% YoY from $56.8 million in Q1 2025, and down 7.91% on a QoQ basis from $52.3 million in Q4 2025.
Aurinia Pharmaceuticals (AUPH) Capital Leases (2023 - 2026) Analysis & Trends
Aurinia Pharmaceuticals (AUPH) has 4 years of Capital Leases data on file, last reported at $48.2 million in Q1 2026.
- Quarterly Capital Leases fell 15.22% year-over-year to $48.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $48.2 million (down 15.22% YoY) and the FY2025 annual result came in at $52.3 million, down 10.64% from the prior year.
- Capital Leases eased to $48.2 million in Q1 2026, from $52.3 million in the prior quarter.
- In the past five years, Capital Leases ranged from a high of $79.4 million in Q2 2023 to a low of $48.2 million in Q1 2026.
- A 4-year average of $63.0 million and a median of $62.1 million in 2024 frame the typical range for Capital Leases.
- The widest YoY moves for Capital Leases: up 8.64% in 2024, down 22.42% in 2024.
- Tracing AUPH's Capital Leases over 4 years: stood at $75.5 million in 2023, then decreased by 22.42% to $58.6 million in 2024, then slipped by 10.64% to $52.3 million in 2025, then declined by 7.91% to $48.2 million in 2026.
- The last three Capital Leases figures came in at $48.2 million (Q1 2026), $52.3 million (Q4 2025), and $55.7 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Aurinia Pharmaceuticals | 2.06 Bn | 1.61 Bn | 76.67 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 43.94 Mn |
| Mar 31, 2026 | 48.18 Mn |
| Dec 31, 2025 | 52.32 Mn |
| Sep 30, 2025 | 55.73 Mn |
| Jun 30, 2025 | 59.28 Mn |
| Mar 31, 2025 | 56.83 Mn |
| Dec 31, 2024 | 58.55 Mn |
| Sep 30, 2024 | 65.96 Mn |
| Jun 30, 2024 | 64.92 Mn |
| Mar 31, 2024 | 67.48 Mn |
| Dec 31, 2023 | 75.48 Mn |
| Sep 30, 2023 | 72.19 Mn |
| Jun 30, 2023 | 79.42 Mn |